Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

VPRIV Important Safety Information

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever.  Generally the infusion-related reactions were mild and, in treatment-naïve patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.  

All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.

As with all therapeutic proteins, there is a potential for immunogenicity. In the clinical studies 1 of 54 treatment-naïve patients treated with VPRIV developed IgG class antibodies.  It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. 

VPRIV is not available in all countries and prescribing information may differ between countries.  Please consult your local prescribing information.  Full prescribing information for VPRIV in the US can be found at www.VPRIV.com.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Oven Industries Inc. announces a new temperature ... has many user-friendly benefits. Contained all in one enclosure, ... a self-contained temperature control system, which has ... device unique, as well as highly convenient for users. ... universally, which allows the user to use the device ...
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... May 17, 2013  Yongye International, Inc. (NASDAQ: ... developer, manufacturer, and distributor of crop nutrient products in ... today announced that, on May 16, 2013, the special ... (the "Board of Directors") was provided a letter (the ... Kong ) Limited ("Abax") to Full Alliance International ...
(Date:5/17/2013)... Canada (PRWEB) May 17, 2013 The ... understanding complex biological systems that can help predict the ... speaker Dr. Sergey Stepaniants, Head of Computational Biology at ... computational biology tools to ensure high-quality genomics when used ... can be applied to complex data sets to identify ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Reportlinker.com announces that a new market research ... Future of White Biotechnology in ... White biotechnology (WB) industry, which ... in biotechnology, is one of the most ...
... (Nasdaq: TELK ) today announced the initiation of ... patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome ... intended to enroll up to 117 evaluable patients. It employs ... transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will ...
... YORK, June 7, 2011 DuPont (NYSE: ... told investors at the JPMorgan Diversified Industries Conference to ... process innovation, selective investment in attractive areas, broad-based growth, ... productivity.  Kullman also reaffirmed DuPont,s 2011 earnings per share ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 3DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3
(Date:5/16/2013)... at MIT may someday eliminate the need for ... their blood-sugar levels and inject themselves with insulin. ... levels in the body and respond by secreting ... function of pancreatic islet cells, which are destroyed ... type of system could ensure that blood-sugar levels ...
(Date:5/16/2013)... and athletes choose to wear the color red when ... Psychological Science , a journal of the Association ... do with their testosterone levels. , The new study, ... of Sunderland and colleagues, demonstrated that males who chose ... higher testosterone levels than other males who chose blue. ...
(Date:5/16/2013)... about 23 million years old give unprecedented insight ... one of the most species-rich groups among the ... Professor Bettina Reichenbacher from the Division of Paleontology ... Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / ... fossils which they assign to the group of ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Oxford, October 10, 2011 - Elsevier, the word-leading ... services, announces the Progress in Nuclear Energy and Education ... March, 2012. The conference, organized by Elsevier ... chaired by Professor Malcolm Joyce of Lancaster University, provides ...
... critical receptor that fuels the brain and without which sentient ... scientists as a promising new drug target for Alzheimer,s and ... is being published online Oct. 11 in Nature Communication ... been shown to be useful as a drug target," says ...
... National Science Foundation (NSF) has selected a team of ... the new Sustainable Cities - People, Infrastructures and the ... is leading the project, which includes 20 U.S. universities, ... grant aims to bring together scientists from all over ...
Cached Biology News:Elsevier organizes Progress in Nuclear Energy and Education Conference 2New drug target for Alzheimer's, stroke is discovered by University at Buffalo scientists 2National Science Foundation selects University of Colorado Denver team to study city sustainability 2
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... a glycoprotein. distributed in colon and ... breast, lung and salivary gland tissues. ... MUC1 and MUC2. Epitope: Tandem ... Immunogen: MUC3 tandem repeat peptide ...
Biology Products: